期刊文献+

Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment 被引量:1

下载PDF
导出
摘要 BACKGROUND Hepatic encephalopathy(HE)can be considered a result of dysregulated gutliver-brain axis function,where cognitive impairment can be reversed or prevented by the beneficial effects induced by"gut-centric"therapies,such as the administration of nonabsorbable disaccharides,nonabsorbable antibiotics,probiotics and prebiotics.AIM To assess the short-term efficacy and safety of the probiotic Escherichia coli Nissle(EcN)1917 strain compared to lactulose and rifaximin in patients with minimal/mild HE.METHODS From January 2017 to March 2020,a total of 45 patients with HE were enrolled in this prospective,single-centre,open-label,randomized study.Participants were randomly assigned at a ratio of 1:1:1 to one of the treatment groups:The EcN group(n=15),lactulose group(n=15)or rifaximin group(n=15)for a 1 mo intervention period.The main primary outcomes of the study were changes in serum ammonia and Stroop test score.The secondary outcomes were markers of a chronic systemic inflammatory response(ІL-6,ІL-8,and IFN-γ)and bacteriology of the stool flora evaluated by specialized nonculture techniques after a 1 mo intervention period.RESULTS Patients who were given rifaximin or EcN showed a more significant reduction in serum ammonia and normalization of Bifidobacteria and Lactobacilli abundance compared to the lactulose group.However,the most pronounced restoration of the symbiotic microflora was associated with EcN administration and characterized by the absence of E.coli with altered properties and pathogenic enterobacteria in patient faeces.In the primary outcome analysis,improvements in the Stroop test parameters in all intervention groups were observed.Moreover,EcN-treated patients performed 15%faster on the Stroop test than the lactulose group patients(P=0.017).Both EcN and rifaximin produced similar significant reductions in the proinflammatory cytokines INF-γ,IL-6 and IL-8.EcN was more efficient than lactulose in reducing proinflammatory cytokine levels.CONCLUSION The use of the probiotic EcN strain was safe and quite efficient for HE treatment.The probiotic reduced the ammonia content and the level of serum proinflammatory cytokines,normalized the gut microbiota composition and improved the cognitive function of patients with HE.The application of the EcN strain was more effective than lactulose treatment.
出处 《World Journal of Hepatology》 2022年第3期634-646,共13页 世界肝病学杂志(英文版)(电子版)
  • 相关文献

参考文献3

二级参考文献10

  • 1Jiannis Vlachogiannakos,Nikos Viazis,Panagiota Vasianopoulou,Irene Vafiadis,Dimitrios G Karamanolis,Spiros D Ladas.Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J].J Gastroenterol Hepatol.2013(3)
  • 2Thomas H. Tranah,Godhev K. Manakkat Vijay,Jennifer M. Ryan,Debbie L. Shawcross.Systemic inflammation and ammonia in hepatic encephalopathy[J].Metabolic Brain Disease.2013(1)
  • 3Alba Moratalla,Isabel Gómez‐Hurtado,Arlette Santacruz,ángela Moya,Gloria Peiró,Pedro Zapater,José M. González‐Navajas,Paula Giménez,José Such,Yolanda Sanz,Rubén Francés.Protective effect of Bifidobacterium pseudocatenulatum CECT 7765 against induced bacterial antigen translocation in experimental cirrhosis[J].Liver Int.2014(6)
  • 4Vipul Jairath,Sunita Rehal,Richard Logan,Brennan Kahan,Sarah Hearnshaw,Simon Stanworth,Simon Travis,Michael Murphy,Kelvin Palmer,Andrew Burroughs.Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit[J].Digestive and Liver Disease.2013
  • 5Saumya Jayakumar,Michelle Carbonneau,Naomi Hotte,A. Dean Befus,Chris St. Laurent,Richard Owen,Mairin McCarthy,Karen Madsen,Robert J. Bailey,Mang Ma,Vince Bain,Kevin Rioux,Puneeta Tandon.VSL #3<sup>?</sup> probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis[J].Liver Int.2013(10)
  • 6Nitin Gupta,Ashish Kumar,Praveen Sharma,Vishal Garg,Barjesh C. Sharma,Shiv K. Sarin.Effects of the adjunctive probiotic VSL #3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial[J].Liver Int.2013(8)
  • 7Radha K. Dhiman.Gut microbiota and hepatic encephalopathy[J].Metabolic Brain Disease.2013(2)
  • 8Genta Kakiyama,William M. Pandak,Patrick M. Gillevet,Phillip B. Hylemon,Douglas M. Heuman,Kalyani Daita,Hajime Takei,Akina Muto,Hiroshi Nittono,Jason M. Ridlon,Melanie B. White,Nicole A. Noble,Pamela Monteith,Michael Fuchs,Leroy R. Thacker,Masoumeh Sikaroodi,Jasmohan S. Bajaj.Modulation of the fecal bile acid profile by gut microbiota in cirrhosis[J].Journal of Hepatology.2013(5)
  • 9Germán Soriano,Elisabet Sánchez,Carlos Guarner.Lactobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis[J].Journal of Hepatology.2012(6)
  • 10Jasmohan S. Bajaj,Phillip B. Hylemon,Jason M. Ridlon,Douglas M. Heuman,Kalyani Daita,Melanie B. White,Pamela Monteith,Nicole A. Noble,Masoumeh Sikaroodi,Patrick M. Gillevet.Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation[J].AJP: Gastrointestinal and Liver Physiology.2012(6)

共引文献68

同被引文献24

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部